CTIS2023-508462-15-00招募中1 期
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions. - TAK-861-2003
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant with a diagnosis of narcolepsy who has completed a controlled study with TAK-861 (including participants diagnosed with NT1 or NT2) and for whom the investigator has no clinical objection to their enrollment.
排除标准
- •Participant has a moderate or severe ongoing treatment emergent adverse event (TEAE) related to the study drug from the parent study or discontinued because of TEAEs in the parent study., Participant has a history of cerebral ischemia, transient ischemic attack (<5 years ago), or cerebral hemorrhage., Participant has a history of myocardial infarction, clinically significant coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure., Participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment, or basal cell skin cancer; these participants may be included after approval by the sponsor or designee)., Participant has a positive urine screen for drugs of abuse (findings confirmed) and/or positive alcohol test during any visit in their prior TAK-861 study, or during the screening period for participants with a dosing gap., Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) on any visit in the parent TAK-861 study, or has positive answers on item 4 or 5 on the Screening/Baseline C-SSRS Lifetime (based on the past year) during the screening assessment for participants with a dosing gap., Participant has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN) at multiple visits in the parent study and the findings are of clinical significance, per investigator or sponsor opinion, or ALT/AST >1.5 times ULN during the screening period for participants with a dosing gap., Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS)., Participant has current active major depressive episode (MDE) or has had an active MDE in the past 6 months., Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention)., Participant has epilepsy or history of seizure., Participant has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires them to take excluded medications.
研究者
相似试验
招募中
2 期
A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia ConditionsNL-OMON53942Takeda Development Center Americas, Inc.2
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-FITakeda Development Center Americas, Inc.160
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-SETakeda Development Center Americas, Inc.160
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-NLTakeda Development Center Americas, Inc.160
进行中（未招募）
1 期
A Study to Evaluate the Long-term Safety and Tolerability of TAK-861arcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)MedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2022-002965-13-FRTakeda Development Center Americas, Inc.160